gefitinib has been researched along with Chronic Lung Injury in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Ando, K; Arata, S; Homma, M; Homma, T; Kishino, Y; Kusumoto, S; Manabe, R; Ohba, M; Ohmori, T; Sagara, H; Takimoto, M; Tsurutani, J; Yamaoka, T | 1 |
Ando, K; Kishino, Y; Kusumoto, S; Manabe, R; Ohmori, T; Sagara, H; Yamaoka, T | 1 |
1 review(s) available for gefitinib and Chronic Lung Injury
Article | Year |
---|---|
Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Injury; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2021 |
1 other study(ies) available for gefitinib and Chronic Lung Injury
Article | Year |
---|---|
Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury.
Topics: ADAM17 Protein; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line; Epithelial Cells; ErbB Receptors; Gefitinib; Heparin-binding EGF-like Growth Factor; Humans; Lung; Lung Injury; Lung Neoplasms; Mice; Mice, Transgenic; Models, Animal; p38 Mitogen-Activated Protein Kinases; Pneumonia; Protein Kinase Inhibitors; Transforming Growth Factor alpha; Tumor Necrosis Factor-alpha | 2019 |